Physician profile

Jessica B Jameson

Pain Medicine (Anesthesiology) · Post Falls, ID

NPI 1669573929

$260,966.41

in general payments reported to CMS, 2019-2025

27 companies · $17K in 2025

The $17K reported for 2025 was more than what 97% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).

See the full distribution for Pain Medicine (Anesthesiology)

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$25,950.00
Consulting Fee$12,540.00
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program$10,470.00
Food and Beverage$4,241.85
Travel and Lodging$2,056.05

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Nevro Corp. $115,336.46 2019-2024 Senza, Omnia
Boston Scientific Corporation $57,090.06 2019-2025 Intracept, Intracept Rf Probe, General - Pain Management
Stimwave Technologies Incorporated $39,622.76 2019-2021
Spr Therapeutics, INC $11,448.59 2023-2025 Sprint Pns System
Vertiflex, INC. $8,670.79 2019
Abbott Laboratories $8,438.84 2019-2025 Proclaim, Eterna
Vertos Medical, INC. $8,373.31 2021-2023 Mild Device Kit
Saluda Medical Americas, INC. $6,371.80 2021-2025 Evoke Scs, Evoke
Medtronic, INC. $1,746.58 2021-2025 Synchromedii, Intellis Adaptivestim, Accurian
Si-Bone, INC. $1,470.98 2021-2025
Sawtooth Surgical Solutions INC $893.96 2024
Relievant Medsystems, INC. $328.76 2019-2023 Intracept
Medtronic USA, INC. $299.13 2019-2020
Arthrex, INC. $217.57 2024
Radius Health, INC. $124.68 2019
Show all 27 companies
CompanyGeneral paymentsYearsTop products
Stryker Corporation $118.89 2020-2025 Ivas
Depuy Synthes Sales INC. $68.35 2024 Teligen, Arch, Vivigen Mis Delivery System
Avanos Medical $56.73 2019
Nalu Medical, INC. $56.53 2020-2021
Mml US, INC. $46.14 2023 Reactiv8
Horizon Therapeutics Plc $36.74 2021
Painteq LLC $36.29 2022-2023 Painteq
Averitas Pharma INC. $27.70 2023 Qutenza
Osteocentric Technologies, INC. $27.45 2024 Osteocentric 4.0 X 130mm Locking Bone Screw Fastener St
Globus Medical, INC. $27.12 2025 Vyrsa V1
Bioventus LLC $18.36 2024 Durolane
Merit Medical Systems INC $11.84 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$354.60 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jessica B Jameson

$260,966.41

in general payments reported 2019-2025

Years
2019-2025
Top company
Nevro Corp.
Context
The $17K reported for 2025 was more than what 97% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).

https://glasscript.com/doctor/347653/jessica-b-jameson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.